[Levosimendan]

Dtsch Med Wochenschr. 2005 Oct 28;130(43):2444-6. doi: 10.1055/s-2005-918588.
[Article in German]
No abstract available

Publication types

  • Review

MeSH terms

  • 3',5'-Cyclic-AMP Phosphodiesterases / antagonists & inhibitors
  • Cardiotonic Agents* / pharmacokinetics
  • Cardiotonic Agents* / pharmacology
  • Cardiotonic Agents* / therapeutic use
  • Cyclic Nucleotide Phosphodiesterases, Type 3
  • Heart Failure / drug therapy*
  • Humans
  • Hydrazones* / pharmacokinetics
  • Hydrazones* / pharmacology
  • Hydrazones* / therapeutic use
  • Phosphodiesterase Inhibitors* / pharmacokinetics
  • Phosphodiesterase Inhibitors* / pharmacology
  • Phosphodiesterase Inhibitors* / therapeutic use
  • Pyridazines* / pharmacokinetics
  • Pyridazines* / pharmacology
  • Pyridazines* / therapeutic use
  • Simendan
  • Vasodilator Agents* / pharmacokinetics
  • Vasodilator Agents* / pharmacology
  • Vasodilator Agents* / therapeutic use

Substances

  • Cardiotonic Agents
  • Hydrazones
  • Phosphodiesterase Inhibitors
  • Pyridazines
  • Vasodilator Agents
  • Simendan
  • 3',5'-Cyclic-AMP Phosphodiesterases
  • Cyclic Nucleotide Phosphodiesterases, Type 3